Atlas Trials

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

Clinical trial NCT03316300 · COMPLETED

Trial details

NCT number
NCT03316300
Sponsor
Neurotech Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Macular Telangiectasia Type 2 (MacTel)
Start date
2017-11-24
Primary completion
2022-08-31
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.